Microbiology and Immunology
Professor of Microbiology and Immunology (primary) Professor of Medicine (secondary)
Education and Training
University of Maryland, College Park, Dept. of Microbiology, College Park, MD; B.S., 1972
University of Maryland, College Park, Dept. of Microbiology, College Park, MD; Ph.D., 1977 (Immunology)
National Institute of Dental Research, National Institutes of Health, Bethesda, MD; Post-doctoral fellow (1977-1980)
For more than ~30 years, my work has focused on the analysis of the fundamental mechanisms by which macrophage differentiation facilitates or restricts infectious agents or tumor growth. My laboratory has made seminal contributions to the area of immunology that we now call “innate immunity,” and specifically, the mechanisms by which Toll-like receptor (TLR) signaling is regulated. We have characterized many of the fundamental mechanisms by which TLR agonists, such as Gram negative lipopolysaccharide (LPS), and cytokines and interferons regulate macrophage functions. Moreover, we have used a model of "endotoxin tolerance" to study the regulation of such signaling pathways.
The creative use of genetic, molecular, and biochemical approaches, combined with unique animal models of infection, has led to our most recent, highly translational work, resulting in novel therapeutic approaches for influenza and respiratory syncytial virus (RSV), development of small molecule TLR antagonists based on the structural interactions of innate signaling molecules, and a prototype vaccine for the biothreat agent, Francisella tularensis.
In toto, I have published ~300 peer-reviewed publications plus ~50 invited works, have mentored 35 post-doctoral fellows and 11 graduate students, and am currently director of a T32 entitled “Signaling pathways in innate immunity.” I have had continuous NIH funding for more than 34 years, including a "NIH Merit Award," in addition to other sources of grant support. Collectively, my record shows that I have developed the scientific expertise and leadership skills required to direct multiple concurrent projects, multi-component projects, and a training program.
macrophages, lipopolysaccharide, Toll-like receptors (TLRs), macrophage differentiation, signaling pathways, interferons, cytokines, influenza, respiratory syncytial virus (RSV), Francisella tularensis, vaccines
A. E. Medvedev, A. Lentschat, D. B. Kuhns, J. C. G. Blanco, C. Salkowski, S. Zhang, M. Arditi, J. I. Gallin, and S. N. Vogel. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and Interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198: 521-531 (2003).
A. A. Awomoyi, P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. G. Blanco, and S. N. Vogel. Association of TLR4 polymorphisms with symptomatic Respiratory Syncytial Virus infection in high-risk infants and young children. J. Immunol. 179: 3171-3177 (2007).
K. A. Shirey, W. Lai, A. J. Scott, M. Lipsky, P. Mistry, L. M. Pletneva, C. L. Karp, J. McAlees, T. L. Gioannini, J. Weiss, W. H. Chen, R, K. Ernst, D. P. Rossignol, F. Gusovsky, J. C. Blanco, and S. N. Vogel. The TLR4 antagonist, Eritoran, protects mice from lethal influenza infection. Nature 497:498-502 (2013) PMC3725830
J. Blanco, M . S. Boukhvalova, L. M. Pletneva, K. Shirey, and S. N. Vogel. A recombinant anchorless Respiratory Syncytial Virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 32:1495-500 (2014). PMC3947896.
D. J. Perkins, R. Rajaiah, S. M. Tennant, G. Ramachandran, T. H. Dyson, and S. N. Vogel. Salmonella typhimurium co-opts the host type I interferon system to selectively restrict macrophage innate immune transcriptional responses. J. Immunol 195: 2461-2471 (2015). PMC4546913
The following link provides a full list of my published work (>300 publications): http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/40447249/?sort=date&direction=ascending
Honors and Awards:
- 1968 Honors Program Scholarship, University of Maryland, College Park, MD
- 1972 B.S. with Highest Honors; Phi Beta Kappa
- 1973 Award from the Department of the Army for computer programming
- 1976 Predoctoral fellowship award from the American Association of University Women
- 1978 USPHS Postdoctoral Fellowship (Accepted); ACS Postdoctoral Fellowship (Not Accepted)
- 1979 Outstanding Young Women of America Award; 1993 Outstanding Instructor Award
- 1997 Special Lecturer Award, 70th Annual Congress of Japanese Society for Bacteriology
- 2000 MERIT Award for NIH Grant AI-18797
- 2001 and 2002 Outstanding Instructor Award, USUHS
- 2004-2006 President, International Endotoxin Society
- 2004 Fellow, American Academy of Microbiology
- 2004 Bonazinga Award (highest scientific award from the Soc. Leukocyte Biology)
- 2004-2009 Yearly teaching commendations from successive UMB medical school Classes of 2007 to 2011
- 2010 Bullard Lecturer, USUHS
- 2011 Fellow, AAAS
- 2014 Milstein Award (highest scientific award from the Intl. Cytokine and Interferon Society)
- 2014 Frederik Bang Award (highest scientific award from the International Endotoxin and Innate Immunity Society)
- 2015 Department of Cell Biology and Molecular Genetics, Univ. of Maryland College Park, Distinguished Alumna Award.
- 2015 Women in Inflammation Award, International Association of Inflammation Societies/Inflammation Research Association.
- American Association of Immunologists (Active)
- American Society of Microbiology (Active)
- Intl. Cytokine and Interferon Society (Active)
- Society for Leukocyte Biology (Active)
- Intl. Endotoxin and Innate Immunity Society (Active; past-President)
- AAAS (Active)
Ongoing Research Support:
R01 AI10451 (MPI: Vogel/Blanco)
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza The goal of this grant is to optimize the protective effect of the TLR4 antagonist, Eritoran, against influenza, in an effort to move it to the clinic. This grant was in response to an RFA for advanced products.
R56 AI18797 (PI: Vogel)
7/1/2015-6/30/2016 (in NCE to 6/30/2017)
Differentiative Signals for Macrophage ActivationThis project analyzes the exogenous and endogenous signals that stimulate macrophages to differentiate. This "bridge loan" grant replaced my continuously funded NIH grant that completed its 32th year of funding on 4/1/15.
T32 AI095150 (PI: Vogel)
NIH/NIAID Signaling Pathways in Innate Immunity
Board Member, Vantage House Life-Time Care Facility, Columbia, MD
- Deputy Editor - Journal of Immunology (1997 – 2003); Section Editor (July 1988 - July 92)
- Editor – Innate Immunity (July 1993 - Present); J. Inflammation (1994 - 97)
- Ad hoc reviewer for J. Immunology, Infection and Immunity, J. Leuk. Biol., Nature, JEM, and others
- Ad hoc reviewer for grants from the NIH, NSF, NRCC, and others
- American Association of Immunologists – Program Committee (1990-93)
- Delegate, Intl. Council, Intl. Soc. for Interferon and Cytokine Res. (Jan. 1991-2000)
- Meeting Committee, Intl Soc. for IFN and Cytokine Research (1995-97); Honors & Awards Cmte (1996 -98)
- Chairman, Board of Academic Councilors, Henry M. Jackson Foundation (1992-97; 2001-2002)
- Member, Board of Directors, FAES (1992-95; 1995-98); Lecturer, FAES Graduate Immunology (1995-2003)
- Ad hoc member of NIAID Council, February 1994; May 2002; NCCAM Council, June 2003
- Honors and Awards Committee, Intl Cytokine Society (1994;1995); Intl Endotoxin Society (1996 - present)
- Scientific Councilor, Intl. Endotoxin Society (1998-2004) and Soc. Leukocyte Biology (1999-2004)
- Nomination Committee, Soc. Leukocyte Biology (2005-2009)
- Review Panel for Research Efforts at CBER, FDA (1998; 2002); FASEB Publications Committee (2003-2006)
- FDA Senior Biomedical Res. Service Credentials Committee (1998);
- President, Intl. Endotoxin and Innate Immunity Soc. (IEIIS) (2004-2006);
- Council Member, NCCAM, NIH (2005-2008)
- Member, External Advisory Committee, Maryland Pathogen Research Institute (MPRI) (2008-present)
- Full Member, Immunity and Host Defense (IHD) study section (2010-2015)